Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of £7,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential.
Aslan touts data for competitor to Dupixent as it seeks new partners
Aslan Pharmaceuticals said Thursday morning that its experimental drug for eczema, or atopic dermatitis, helped more patients achieve nearly clear or clear skin compared to